论文部分内容阅读
目的:研究孟鲁斯特联合雾化吸入剂对稳定期COPD患者气道功能及炎症反应程度的影响。方法:选择2012年6月至2015年8月期间在我院就诊的98例稳定期慢性阻塞性肺疾病患者作为研究对象,随机分为观察组和对照组,观察组接受孟鲁斯特口服联合糖皮质激素雾化吸入治疗,对照组患者接受糖皮质激素雾化吸入治疗,比较两者患者的气道功能指标及血清炎症介质含量。结果:治疗后,与对照组比较,观察组患者的FEV1/FVC、MMEF、PEF均较高,血清TNF-α、IL-6和IL-8含量均较低,两组间的差异有显著性(P<0.05)。结论:孟鲁斯特联合雾化吸入剂治疗稳定期COPD能够改善气道功能、抑制炎症反应,临床应用价值优于雾化吸入剂单独治疗。
Objective: To study the effects of combination of inhalational montelukast on airway function and inflammatory response in stable COPD patients. Methods: A total of 98 patients with chronic obstructive pulmonary disease (COPD) treated in our hospital from June 2012 to August 2015 were randomly divided into observation group and control group. The observation group received Montelukast oral combined Corticosteroid inhalation therapy, patients in the control group received glucocorticoid inhalation therapy, airway function index and serum inflammatory mediators in both groups were compared. Results: Compared with the control group, FEV1 / FVC, MMEF and PEF in the observation group were significantly higher and the levels of serum TNF-α, IL-6 and IL-8 were lower in the observation group after treatment (P <0.05). CONCLUSIONS: Montelukast combined with inhalation of nebulizer in the treatment of stable COPD can improve airway function and inhibit the inflammatory reaction, and its clinical value is superior to that of inhalation alone.